Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer

British Journal of Surgery

Volumn 93, Issue 8, 2006, Pages 961-968

  Tilanus Linthorst, M M A ^a   Alves, C ^a   Seynaeve, C ^a   Menke Pluymers, M B E ^a   Eggermont, A M M ^a   Brekelmans, C T M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; ONSET AGE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PEDIGREE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 33747038974     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5344     Document Type: Article

References (27)

1. Peto J, Easton DF, Matthews FE, Ford D, Swerdlow AJ. Cancer mortality in relatives of women with breast cancer: the OPCS study. Office of Population Censuses and Surveys. Int J Cancer 1996; 65: 275-283.
2. Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 1993; 270: 1563-1568.
3. Eerola H, Vahteristo P, Sarantaus L, Kyyronen P, Pyrhonen S, Blomqvist C et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer 2001; 93: 368-372.
4. Malone KE, Daling JR, Weiss NS, McKnight B, White E, Voigt LF. Family history and survival of young women with invasive breast carcinoma. Cancer 1996; 78: 1417-1425.
5. Cook LS, White E, Schwartz SM, McKnight B, Daling JR, Weiss NS. A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control 1996; 7: 382-390.
6. Eccles D, Simmonds P, Goddard J, Coultas M, Hodgson S, Lalloo F et al. Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam Cancer 2001; 1: 65-72.
7. Möller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002; 101: 555-559.
8. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen F et al. Excess risk for contralateral breast cancer in CHEK2* 1100delC germline mutation carriers. Breast Cancer Res Treat 2004; 83: 91-93.
9. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 855-861.
10. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91: 943-949.
11. Eccles DM, Pichert G. Familial non-BRCA1/BRCA2-associated breast cancer. Lancet Oncol 2006; 6: 705-711.
12. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van der Vijver MJ et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6: 782-789.
13. Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 2003; 97: 1-11.
14. Eerola H, Heikkilä P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005; 7: R93-R100.
15. Tilanus-Linthorst MM, Bartels KC, Alves C, Bakri B, Crepin E, van den Ouweland A et al. Selection bias influence reported contralateral breast cancer incidence and survival in high-risk non-BRCA1/2 patients. Br Cancer Res Treat 2006; 95: 117-123.
16. Heron DE, Komarnicky LT, Hyslop T, Schwartz TF, Mansfield CM. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 2000; 88: 2739-2750.
17. Newman LA, Sahin AA, Cunningham JE, Bondy ML, Mirza NQ, Vlastos GS et al. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer 2001; 91: 1845-1853.
18. Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005; 23: 4275-4286.
19. Verhoog LC, Brekelmans CTM, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 2000; 83: 384-386.
20. de Bock GH, Schutte M, Krol-Warmerdam EMM, Seynaeve C, Blom J, Brekelmans CT et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2* 1100delC variant. J Med Genet 2004; 41: 731-735.
21. Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 2005; 103: 44-51.
22. Brekelmans CT, Voogd AC, Botke BN, van Geel BN, Rodrigus P, Rutgers EJ et al. Family history of breast cancer and local recurrence after breast-conserving therapy. The Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Eur J Cancer 1999; 35: 620-626.
23. Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004; 22: 1823-1829.
24. Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003; 138: 1323-1328.
25. van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005; 93: 287-292.
26. Tilanus-Linthorst MMA, Kriege M, Boetes C, Hop WC, Obdeijn IM, Oosterwijk JC et al. Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 2005; 41: 1610-1617.
27. Michaelson JS, Silverstein M, Sgroi D, Cheongsiaatmoy JA, Taghian A, Powell S et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003; 981: 2133-2143.